Research Topics
| H E HeslopSummaryAffiliation: Baylor College of Medicine Country: USA Publications
Research Grants
| Collaborators
|
Detail Information
Publications
Gene therapyH E Heslop
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Cytotherapy 9:519-20. 2007
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipientsHelen E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 115:925-35. 2010....
How I treat EBV lymphoproliferationHelen E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 114:4002-8. 2009..Major challenges remain for defining indications for preemptive therapies and integrating novel and conventional therapies...
Reconstitution of adenovirus-specific cell-mediated immunity in pediatric patients after hematopoietic stem cell transplantationG D Myers
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Bone Marrow Transplant 39:677-86. 2007..In conclusion, recipients of alternative donor transplants at our institution have significantly delayed adv-specific cellular immune recovery, which correlates to an increased risk of adv-associated morbidity and mortality...
Cytomegalovirus (CMV) infections and CMV-specific cellular immune reconstitution following reduced intensity conditioning allogeneic stem cell transplantation with AlemtuzumabR Lamba
Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
Bone Marrow Transplant 36:797-802. 2005..However, in the majority of patients, infection is transient, and antiviral T cell reconstitution is rapid. Monitoring with CMV-specific CTLs may help identify the subset of patients at risk from recurrent infection or disease...
Gene and cell transfer for specific immunotherapyM K Brenner
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Vox Sang 74:87-90. 1998..In a number of settings, gene modified tumor vaccines, cytotoxic T cells and dendritic cells are producing both immunomodulation and clinically evident benefits. Continued exploration of this approach seems well justified...
Adenoviral gene transfer into dendritic cells efficiently amplifies the immune response to LMP2A antigen: a potential treatment strategy for Epstein-Barr virus--positive Hodgkin's lymphomaB Gahn
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Int J Cancer 93:706-13. 2001..Hence, recombinant adenoviruses encoding LMP2A effectively transduce DCs and direct the generation of LMP2A-specific CTLs. This approach will be a potent strategy in Hodgkin's lymphoma immunotherapy...
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safetyV Hoyos
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Leukemia 24:1160-70. 2010..In summary, this strategy safely increases the anti-lymphoma/leukemia effects of CAR.19-redirected T lymphocytes and may be a useful approach for treatment of patients with B-cell malignancies...
Adenovirus infection rates in pediatric recipients of alternate donor allogeneic bone marrow transplants receiving either antithymocyte globulin (ATG) or alemtuzumab (Campath)G D Myers
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children's Hospital, Houston, 77030, USA
Bone Marrow Transplant 36:1001-8. 2005..This work will help in identifying at-risk populations for our upcoming immunotherapy trial using adoptively transferred donor-derived adenovirus-specific cytotoxic T lymphocytes...
Generation of autologous Epstein-Barr virus-specific cytotoxic T cells for adoptive immunotherapy in solid organ transplant recipientsB Savoldo
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Transplantation 72:1078-86. 2001....
EBV specific CTL: a model for immune therapyC M Rooney
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Vox Sang 74:497-8. 1998..We are now studying other virally-linked malignancies to discover whether a similar approach will be of therapeutic value...
Outcome of reduced-intensity allogeneic hematopoietic stem cell transplantation (RISCT) using antilymphocyte antibodies in patients with high-risk acute myeloid leukemia (AML)U Popat
Department of Medicine, Baylor College of Medicine and The Methodist Hospital, Houston, TX, USA
Bone Marrow Transplant 37:547-52. 2006..Hence, RISCT using lymphodepleting antibodies may be of value for older patients with AML, even in those with active or high-risk disease, and even if they lack an MHC-identical sibling donor...
Human herpesvirus-6 encephalitis following allogeneic hematopoietic stem cell transplantationT Vu
Center for Cell and Gene Therapy, Baylor College of Medicine and The Methodist Hospital, Houston, TX 77030, USA
Bone Marrow Transplant 39:705-9. 2007..Given this high incidence of HHV-6 and the possibility of successful outcome with prompt treatment, a high index of suspicion of this disorder is required in recipients of monoclonal antibody supported allografts...
T cell therapiesS Gottschalk
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin Street MC 3-3320, 77030 Houston, USA
Ernst Schering Found Symp Proc 4:69-82. 2006..Strategies on how to improve the antitumor activity of EBV-specific CTL are being discussed. If effective, these strategies will have broad implications for T cell therapies for a range of human tumors with defined antigens...
Flanking-sequence exponential anchored-polymerase chain reaction amplification: a sensitive and highly specific method for detecting retroviral integrant-host-junction sequencesM A Pule
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
Cytotherapy 10:526-39. 2008..At present, most measures to assess IHJ are complex, insensitive and may be subject to IHJ selection bias inherent to the technology used...
Comparable outcome of alternative donor and matched sibling donor hematopoietic stem cell transplant for children with acute lymphoblastic leukemia in first or second remission using alemtuzumab in a myeloablative conditioning regimenAlana A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1245-52. 2008..For children undergoing stem cell transplantation (SCT) from alternative donors, alemtuzumab with a myeloablative conditioning regimen resulted in DFS comparable to MSD...
Transmission of integrated human herpesvirus-6 in allogeneic hematopoietic stem cell transplantationR T Kamble
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX, USA
Bone Marrow Transplant 40:563-6. 2007..CI of HHV-6 may confound the interpretation of HHV-6 viremia after stem cell transplantation; consideration of the possibility of CI HHV-6 will avoid unnecessary antiviral therapy...
Outcome of hematopoietic stem cell transplant as salvage therapy for Hodgkin's lymphoma in adolescents and young adults at a single institutionJ A Shafer
Center for Cell and Gene Therapy, Houston, TX 77030, USA
Leuk Lymphoma 51:664-70. 2010..Our data show encouraging outcomes for patients with chemosensitive relapsed HL who receive hematopoietic stem cell transplant (HSCT) and support the value of the procedure even when the disease is chemoresistant...
Gene therapy for paediatric leukaemiaR F Rousseau
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX, USA
Expert Opin Biol Ther 1:663-74. 2001..With the continued scientific advancements in this field, gene therapy will almost certainly have a major impact on the treatment of paediatric leukaemia in the future...
Selective elimination of a chemoresistant side population of B-CLL cells by cytotoxic T lymphocytes in subjects receiving an autologous hCD40L/IL-2 tumor vaccineA E Foster
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Leukemia 24:563-72. 2010..Hence, malignant B cells with a primary drug-resistant phenotype can be targeted by T- cell-mediated effector activity after immunization of human subjects...
T-cell immunotherapy for adenoviral infections of stem-cell transplant recipientsA M Leen
Center for Cell and Gene Therapy, Department of Pediatrics-Hem/Onc, Baylor College of Medicine, 6621 Fannin St, MC3-3320 Houston, TX 77030, USA
Ann N Y Acad Sci 1062:104-15. 2005..Thus, we have characterized human T-cell responses to adenovirus in vitro and explored the potential of adoptive T-cell immunotherapy as a prophylactic or therapeutic strategy for adenovirus infections posttransplant...
Comparable outcomes of matched-related and alternative donor stem cell transplantation for pediatric severe aplastic anemiaAlana A Kennedy-Nasser
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 12:1277-84. 2006..We conclude that, for children with SAA, AD transplantation is as effective as MSD transplantation. Further, compared with ATG, preparatory regimens containing Campath may be associated with a lower incidence of extensive, chronic GHVD...
Gene-marking studies of hematopoietic cellsC M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Int J Hematol 73:14-22. 2001..With continuing advances in gene-marking technology, the value of the information provided by these studies increases, thereby ensuring their continued relevance to the field of gene transfer...
Immunotherapy for Hodgkin's diseaseC M Rooney
Centre for Cell and Gene Therapy, Department of Pediatrics, Division of Hematology and Oncology, Department of Molecular Virology and Microbiology, Baylor College of Medicine, Houston, Texas, USA
Ann Hematol 81:S39-42. 2002..Future clinical studies will test the efficacy of CTL with improved antigen-specificity and resistance to Hodgkin immune evasion strategies...
Options for T-cell based therapiesH E Heslop
Center for Gene and Cell Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Vox Sang 87:230-4. 2004
Is retroviral gene marking too dangerous to use?M K Brenner
Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Cytotherapy 5:190-3. 2003
Gene therapy of pediatric leukemiaH E Heslop
Department of Medicine, Baylor College of Medicine, Houston, Texas, USA
Clin Lab Med 20:183-95, x. 2000..Some of these approaches are now being evaluated in clinical trials...
Efficient infection of primitive hematopoietic stem cells by modified adenovirusP Yotnda
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Gene Ther 8:930-7. 2001..The ability of Ad5/F35 to deliver transgenes to primitive HPC with high efficiency and low toxicity in the absence of growth factors provides an improved means of studying the consequences of transient gene expression in these cells...
Immunotherapy targeting EBV-expressing lymphoproliferative diseasesCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
Best Pract Res Clin Haematol 21:405-20. 2008..A number of strategies to genetically modify the infused T cells and modulate the host environment are under evaluation...
Regression of experimental medulloblastoma following transfer of HER2-specific T cellsNabil Ahmed
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, The Methodist Hospital, Houston, Texas 77030, USA
Cancer Res 67:5957-64. 2007..In contrast, delivery of nontransduced T cells did not change the tumor growth pattern. Adoptive transfer of HER2-specific T cells may represent a promising immunotherapeutic approach for medulloblastoma...
Adoptive cellular immunotherapy for viral diseasesY Fujita
Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
Bone Marrow Transplant 41:193-8. 2008..Current efforts are focused on providing protection toward a broader range of viruses safely, rapidly and effectively...
In vivo expansion of LMP 1- and 2-specific T-cells in a patient who received donor-derived EBV-specific T-cells after allogeneic stem cell transplantationCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Leuk Lymphoma 47:837-42. 2006....
Inducible caspase 9 suicide gene to improve the safety of allodepleted T cells after haploidentical stem cell transplantationSiok Keen Tey
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 13:913-24. 2007..We have demonstrated the clinical feasibility of this approach after haploidentical transplantation by scaling up production using clinical grade materials...
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytesConcetta Quintarelli
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 110:2793-802. 2007..We found that the incorporation of an inducible caspase-9 suicide gene allowed efficient elimination of transgenic CTLs after exposure to a chemical inducer of dimerization, thereby increasing the safety and feasibility of the approach...
Exploiting cytokine secretion to rapidly produce multivirus-specific T cells for adoptive immunotherapyYuriko Fujita
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Texas Children s Hospital, Houston, TX 77030, USA
J Immunother 31:665-74. 2008..By simultaneously expanding a portion of the selected product, we can characterize phenotype and function of the infused product and link them with subsequent in vivo outcome...
Enhancing the in vivo expansion of adoptively transferred EBV-specific CTL with lymphodepleting CD45 monoclonal antibodies in NPC patientsChrystal U Louis
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Blood 113:2442-50. 2009..Lymphodepleting mAbs prior CTL transfer may represent an alternative to chemotherapy to enhance expansion of infused CTL. This study is registered at (http://www.clinialtrials.gov) as NCT00608257...
Cytotoxic T lymphocyte therapy with donor T cells prevents and treats adenovirus and Epstein-Barr virus infections after haploidentical and matched unrelated stem cell transplantationAnn M Leen
Center for Cell and Gene Therapy and Departments of Pediatrics, Immunology, Medicine, and Virology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, TX 77030, USA
Blood 114:4283-92. 2009..This trial was registered at www.clinicaltrials.gov as #NCT00590083...
Prompt versus preemptive intervention for EBV lymphoproliferative diseaseHans-Joachim Wagner
Departments of Pediatrics and Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Blood 103:3979-81. 2004..Hence, quantitative measurement of EBV DNA may best be used to enable the prompt rather than the preemptive treatment of PTLD...
Generation of Epstein-Barr virus-specific cytotoxic T lymphocytes resistant to the immunosuppressive drug tacrolimus (FK506)Biagio De Angelis
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 114:4784-91. 2009....
Children with acute leukemia: a comparison of outcomes from allogeneic blood stem cell and bone marrow transplantationYu Feng Lin
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Pediatr Blood Cancer 56:143-51. 2011..In a retrospective study, we compared allogeneic PBSCT (n = 30) with BMT (n = 110) in children with acute leukemia between January 2001 and September 2006...
T lymphocytes redirected against the kappa light chain of human immunoglobulin efficiently kill mature B lymphocyte-derived malignant cellsJuan Vera
Center for Cell and Gene Therapy, Baylor College of Medicine, Fannin St, MC 3-3320, Houston, TX 77030, USA
Blood 108:3890-7. 2006....
The costs and cost-effectiveness of allogeneic peripheral blood stem cell transplantation versus bone marrow transplantation in pediatric patients with acute leukemiaYu Feng Lin
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030, USA
Biol Blood Marrow Transplant 16:1272-81. 2010..More studies using larger and randomized controlled trials are needed to confirm the long-term cost-effectiveness of each procedure...
Complete responses of relapsed lymphoma following genetic modification of tumor-antigen presenting cells and T-lymphocyte transferCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX 77030, USA
Blood 110:2838-45. 2007..This study is registered at http://www.cancer.gov/clinicaltrials (protocol IDs: BCM-H-9936, NCT00062868, NCT00070226)...
T-cell-based therapies for malignancy and infection in childhoodNabil Ahmed
Department of Pediatrics, Center for Cell and Gene Therapy, Baylor College of Medicine, 1102 Bates Street, Suite 1770, MC3 3320, Houston, TX 77030, USA
Pediatr Clin North Am 57:83-96. 2010....
HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumorsNabil Ahmed
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Clin Cancer Res 16:474-85. 2010....
Autologous Epstein-Barr virus (EBV)-specific cytotoxic T cells for the treatment of persistent active EBV infectionBarbara Savoldo
Center for Cell and Gene Therapy, Houston, TX 77030, USA
Blood 100:4059-66. 2002....
Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes for the prevention and treatment of EBV-associated post-transplant lymphomasZhensheng Liu
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
Recent Results Cancer Res 159:123-33. 2002....
Successful treatment of stem cell graft failure in pediatric patients using a submyeloablative regimen of campath-1H and fludarabineNabil Ahmed
Center for Cell and Gene Therapy, Texas Children s Hospital, Baylor College of Medicine, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 14:1298-304. 2008..Thus, the regimen that we describe can be used with minimal toxicity to effectively overcome graft failure after myeloablative HSCT in children...
An inducible caspase 9 suicide gene to improve the safety of mesenchymal stromal cell therapiesCarlos Almeida Ramos
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas, USA
Stem Cells 28:1107-15. 2010..We believe that this approach will become of increasing value as clinical applications for MSCs develop further...
Adoptive T-cell therapy for EBV-associated post-transplant lymphoproliferative diseaseCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Acta Haematol 110:139-48. 2003..The infusion of EBV-CTL has been demonstrated to be safe and effective in allogeneic HSCT recipients and their use post-SOT is being evaluated...
Derivation of human T lymphocytes from cord blood and peripheral blood with antiviral and antileukemic specificity from a single culture as protection against infection and relapse after stem cell transplantationKenneth P Micklethwaite
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, TX, USA
Blood 115:2695-703. 2010..This approach may prove beneficial for patients with high-risk B-ALL who have recently received an HSC or CB transplant and are at risk of infection and relapse...
Treatment of nasopharyngeal carcinoma with Epstein-Barr virus--specific T lymphocytesKarin C M Straathof
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, 1102 Bates St, Suite 1120, Houston, TX 77030, USA
Blood 105:1898-904. 2005..These results demonstrate that administration of EBV-specific CTLs to patients with advanced NPC is feasible, appears to be safe, and can be associated with significant antitumor activity...
Cellular therapy of Epstein-Barr-virus-associated post-transplant lymphoproliferative diseaseHelen E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hosptial and Texas Children s Hospital, Houston, TX 77030, USA
Best Pract Res Clin Haematol 17:401-13. 2004..The use of genetically modified T cells or newer suicide genes may result in improved safety and efficacy. Current challenges are to define indications for immunotherapy or antibody therapy in patients with incipient or overt PTLD...
Cellular immunity to Epstein-Barr virus in liver transplant recipients treated with rituximab for post-transplant lymphoproliferative diseaseBarbara Savoldo
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Houston, Texas, USA
Am J Transplant 5:566-72. 2005..Rituximab effectively induced regression of PTLD in OLT recipients. However, EBV-specific T-cell immunocompetence, which may be crucial for the long-term control of EBV-mediated proliferation, did not improve...
Hematopoietic stem cell transplantation in patients with sporadic amyotrophic lateral sclerosisS H Appel
Department of Neurology, Methodist Neurological Institute, Houston, TX 77030, USA
Neurology 71:1326-34. 2008..Amyotrophic lateral sclerosis (ALS), an inexorably progressive motoneuron disease, is accompanied by significantly increased markers of inflammation. These inflammatory constituents could protect, harm, do neither, or do both...
CD52 and CD45 monoclonal antibodies for reduced intensity hemopoietic stem cell transplantation from HLA matched and one antigen mismatched unrelated donorsU Popat
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
Bone Marrow Transplant 35:1127-32. 2005....
Comparison of the efficiency of transduction of leukemic cells by fiber-modified adenovirusesP Yotnda
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Hum Gene Ther 15:1229-42. 2004..Ad5F/K21 and Ad5F/RGD should be of value for the genetic modification of human primary leukemia cells...
Immune therapy for EBV infections after hemopoietic stem-cell transplantH E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston TX 77030, USA
Cytotherapy 4:433-4. 2002
T lymphocytes coexpressing CCR4 and a chimeric antigen receptor targeting CD30 have improved homing and antitumor activity in a Hodgkin tumor modelAntonio Di Stasi
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children s Hospital, Houston, 77030, USA
Blood 113:6392-402. 2009..This approach may be of value in patients affected by HL...
Diagnosis and treatment of posttransplantation lymphoproliferative disease after hematopoietic stem cell transplantationHans-Joachim Wagner
Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas, USA
Biol Blood Marrow Transplant 8:1-8. 2002..A major remaining challenge is to assess the significance of an elevated EBV load posttransplantation and to determine the indications for preemptive treatment...
Treatment of solid organ transplant recipients with autologous Epstein Barr virus-specific cytotoxic T lymphocytes (CTLs)Barbara Savoldo
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
Blood 108:2942-9. 2006..These data are consistent with an expansion and persistence of adoptively transferred EBV-CTLs that is limited in the presence of continued immunosuppression but that nonetheless produces clinically useful antiviral activity...
Cytotoxic T lymphocyte therapy for Epstein-Barr virus+ Hodgkin's diseaseCatherine M Bollard
Center for Gene and Cell Therapy, Baylor College of Medicine, 6621 Fannin St, MC 3 3320, Houston, TX 77030, USA
J Exp Med 200:1623-33. 2004..One additional patient had a partial response, and five had stable disease. The performance and fate of these human tumor antigen-specific T cells in vivo suggests that they might be of value for the treatment of EBV+ Hodgkin lymphoma...
Adoptive immunotherapy for EBV-associated malignanciesStephen Gottschalk
Center for Cell and Gene Therapy, Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Leuk Lymphoma 46:1-10. 2005..To overcome these immune evasion strategies a number of approaches have been developed including targeting CTL to subdominant EBV antigens and genetically modifying CTL to increase their potency...
Adoptive T cell therapy of cancerMalcolm K Brenner
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, TX, USA
Curr Opin Immunol 22:251-7. 2010..Current research focuses on defining the optimum type of cell for transfer, genetically modifying infused T cells to augment function and overcome tumor evasion strategies and modulating the host environment...
The generation and characterization of LMP2-specific CTLs for use as adoptive transfer from patients with relapsed EBV-positive Hodgkin diseaseCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
J Immunother 27:317-27. 2004..This approach is being used in a current clinical trial...
Adoptive immunotherapy for posttransplantation viral infectionsCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, Houston, TX 77030, USA
Biol Blood Marrow Transplant 10:143-55. 2004..The use of genetically modified T cells or the use of newer suicide genes may result in improved safety and efficacy...
Antitumor activity of EBV-specific T lymphocytes transduced with a dominant negative TGF-beta receptorAaron E Foster
Center for Cell and Gene Therapy, The Methodist Hospital and Texas Children s Hospital, Department of Pediatrics, Baylor College of Medicine, Houston, TX, USA
J Immunother 31:500-5. 2008..TGF-beta-resistant CTL had a functional advantage over unmodified CTL in the presence of TGF-beta-secreting EBV-positive lymphoma, and had enhanced antitumor activity, supporting the potential value of this countermeasure...
Quantitative EBV viral loads and immunosuppression alterations can decrease PTLD incidence in pediatric liver transplant recipientsTimothy C Lee
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, Texas, USA
Am J Transplant 5:2222-8. 2005..05). These findings illustrate that frequent EBV viral load monitoring and preemptive immunosuppression modulation have an integral role in preventing PTLD in the pediatric liver transplant population...
Immunotherapy for Epstein-Barr virus-associated cancers in childrenKarin C M Straathof
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Oncologist 8:83-98. 2003..If these strategies to improve the therapeutic potential of immunotherapy for EBV-associated tumors prove successful, this type of treatment may be adapted to other tumors expressing known (viral) antigens...
Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individualsAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Nat Med 12:1160-6. 2006..Monoculture-derived multispecific CTL infusion could provide a safe and efficient means to restore virus-specific immunity in the immunocompromised host...
Hematopoietic and immunomodulatory effects of lytic CD45 monoclonal antibodies in patients with hematologic malignancyRobert A Krance
Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Biol Blood Marrow Transplant 9:273-81. 2003..The in vivo myeloreductive and lymphoreductive properties of lytic CD45 MAb in humans, therefore, closely parallel the activity seen in a murine model and, therefore, may be of similar value...
Haemopoietic stem cell transplantation for acute lymphoblastic leukaemiaUday Popat
Department of Medicine, Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
Cancer Treat Rev 29:3-10. 2003..Relapse remains the major cause of transplant failure and immunotherapy strategies post-transplant to augment the graft versus leukaemia effect are being explored...
Viral lymphomagenesisNabil Ahmed
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, Texas 77030, USA
Curr Opin Hematol 13:254-9. 2006..The presence of viral genomes in these lymphomas, however, offers targets for intervention and approaches under evaluation include adoptive immunotherapy, interferon, and small molecules targeting aspects of virus biology...
Adoptive T-cell transfer in cancer immunotherapySiok-Keen Tey
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, 77030, USA
Immunol Cell Biol 84:281-9. 2006....
Use of cytokine polymorphisms and Epstein-Barr virus viral load to predict development of post-transplant lymphoproliferative disorder in paediatric liver transplant recipientsTimothy C Lee
Michael E DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Clin Transplant 20:389-93. 2006..Herein we describe the use of cytokine polymorphisms and real-time quantitative polymerase chain reaction (qPCR) Epstein-Barr virus (EBV) viral load to identify patients at risk for PTLD development...
A strategy for treatment of Epstein-Barr virus-positive Hodgkin's disease by targeting interleukin 12 to the tumor environment using tumor antigen-specific T cellsHans-Joachim Wagner
Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Cancer Gene Ther 11:81-91. 2004..Tumor-specific, Flexi-IL12-transduced EBV-specific CTL should have a functional advantage over unmodified CTL, particularly in the presence of the adverse Th2 cytokine environment produced by Hodgkin tumor cells...
Accelerated production of antigen-specific T cells for preclinical and clinical applications using gas-permeable rapid expansion cultureware (G-Rex)Juan F Vera
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston, TX 77030, USA
J Immunother 33:305-15. 2010..This bioprocess optimization increased T-cell output while decreasing the complexity and cost of CTL manufacture, making cell therapy more accessible...
Administration of latent membrane protein 2-specific cytotoxic T lymphocytes to patients with relapsed Epstein-Barr virus-positive lymphomaCatherine M Bollard
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children's Hospital, Houston, 77030, USA
Clin Lymphoma Myeloma 6:342-7. 2006
Functionally active virus-specific T cells that target CMV, adenovirus, and EBV can be expanded from naive T-cell populations in cord blood and will target a range of viral epitopesPatrick J Hanley
Department of Immunology, Baylor College of Medicine, Texas Children s Hospital and The Methodist Hospital, Center for Cell and Gene Therapy, Houston, TX 77030, USA
Blood 114:1958-67. 2009..This study is registered at www.clinicaltrials.gov as NCT00078533...
Post-transplant lymphoproliferative disordersStephen Gottschalk
Center for Cell and Gene Therapy, Texas Children s Cancer Center, Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Annu Rev Med 56:29-44. 2005..Despite these advances, it remains a major challenge to define indications for preemptive therapies for PTLD and to integrate novel therapeutic approaches with conventional therapies...
Adoptive T-cell therapy for Epstein-Barr virus-positive Hodgkin's diseaseM Helen Huls
Center for Cell and Gene Therapy, Baylor College of Medicine, Houston Texas 77030, USA
Acta Haematol 110:149-53. 2003..A number of approaches to overcome these tumor evasion strategies including targeting CTLs to the expressed antigens and genetic modification of CTLs are being evaluated...
Cytotoxic T lymphocytes as immune-therapy in haematological practiceAnn M Leen
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital, and Texas Children s Hospital, Houston, TX 77030, USA
Br J Haematol 143:169-79. 2008....
Characterization of latent membrane protein 2 specificity in CTL lines from patients with EBV-positive nasopharyngeal carcinoma and lymphomaKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Medicine, Methodist Hospital and Texas Children's Hospital, Houston, TX 77030, USA
J Immunol 175:4137-47. 2005..These new LMP2 epitopes broaden the diversity of HLA alleles with available epitopes, and, in particular, those epitopes conserved between EBV strains provide valuable tools for immunotherapy and immune monitoring...
Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expressionNabil Ahmed
Center for Cell and Gene Therapy, Baylor College of Medicine, Texas Children s Hospital, Houston, Texas 77030, USA
Mol Ther 17:1779-87. 2009..Genetic modification of T cells with CARs specific for target antigens, expressed at too low a level to be effectively recognized by monoclonal antibodies, may allow immunotherapy to be more broadly applicable for human cancer therapy...
The clone ranger?Helen E Heslop
Center for Cell and Gene Therapy, Baylor College of Medicine, The Methodist Hospital and Texas Children s Hospital, Houston, Texas 77030, USA
Mol Ther 16:1520-1. 2008
Transfusion-related acute lung injury (TRALI) following allogeneic stem cell transplant for acute myeloid leukemiaSiddhartha Ganguly
Center for Gene and Cell Therapy, Baylor College of Medicine, Houston, Texas 77030, USA
Am J Hematol 75:48-51. 2004..As there is a wide differential diagnosis for pulmonary infiltrates developing post transplant, TRALI may be under-recognized and should be considered in this setting...
Treatment of Epstein-Barr virus-associated malignancies with specific T cellsStephen Gottschalk
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, Texas, USA
Adv Cancer Res 84:175-201. 2002..If effective, such strategies could be applied not only to other EBV-associated malignancies, but also to a broad range of human tumors with defined tumor antigens and similar immune evasion strategies...
Complement-fixing CD45 monoclonal antibodies to facilitate stem cell transplantation in mouse and manMalcolm K Brenner
Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, Texas 77030, USA
Ann N Y Acad Sci 996:80-8. 2003..These pre-clinical and clinical results warrant further evaluation of anti-CD45 MAbs in subablative preparative regimens for stem cell transplantation...
Generation of EBV-specific CD4+ cytotoxic T cells from virus naive individualsBarbara Savoldo
Center for Cell and Gene Therapy and Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
J Immunol 168:909-18. 2002..In addition, our method for selecting EBV-specific CTL from naive individuals by precursor cell enrichment may be applicable to the immunotherapy of cancer patients with a low frequency of tumor- or virus-specific CTL...
Quantification of a low cellular immune response to aid in identification of pediatric liver transplant recipients at high-risk for EBV infectionTimothy C Lee
Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX 77030, USA
Clin Transplant 20:689-94. 2006..Because measurement of EBV DNA load as a single parameter has a poor positive predictive value for development of PTLD, the association of these assays may be of help in the identification of patients at risk for PTLD...
Immunotherapy of high-risk acute leukemia with a recipient (autologous) vaccine expressing transgenic human CD40L and IL-2 after chemotherapy and allogeneic stem cell transplantationRaphael F Rousseau
Center for Cell and Gene Therapy, 6621 Fannin St, MC3 3320, Houston, TX 77030, USA
Blood 107:1332-41. 2006..This approach may be worthy of further study, particularly in patients with a high risk of relapse...
Guillain-Barré syndrome after allogeneic hematopoietic stem cell transplantationV Rodriguez
Center for Cell and Gene Therapy, Texas Children's Hospital, Houston, TX, USA
Bone Marrow Transplant 29:515-7. 2002..We review possible factors contributing to the development of this syndrome in these three patients...
An inducible caspase 9 safety switch for T-cell therapyKarin C Straathof
Center for Cell and Gene Therapy, Baylor College of Meidcine, Houston, TX 77030, USA
Blood 105:4247-54. 2005..Third, inducible caspase 9 maintains function in T cells overexpressing antiapoptotic molecules. These characteristics favor incorporation of inducible caspase 9 as a safety feature in human T-cell therapies...
Adapting a transforming growth factor beta-related tumor protection strategy to enhance antitumor immunityCatherine M Bollard
Center for Cell and Gene Therapy, Department of Pediatrics, Baylor College of Medicine, Houston, TX 77030, USA
Blood 99:3179-87. 2002..Tumor-specific CTLs expressing HATGF-betaRII-Deltacyt should have a selective functional and survival advantage over unmodified CTLs in the presence of TGF-beta-secreting tumors and may be of value in treatment of these diseases...
Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignanciesStephen Gottschalk
Center for Cell and Gene Therapy, Texas Children s Cancer Center, Departments of Pediatrics, Medicine, and Molecular Virology and Microbiology, Baylor College of Medicine, Houston, TX 77030, USA
Blood 101:1905-12. 2003..Targeting LMP1 in these malignancies may improve the efficacy of current adoptive immunotherapy approaches...
Research Grants
- Enhancing T Cell Therapy of CancerHelen Heslop; Fiscal Year: 2006..Not Available ..
- Training in Cell and Gene TherapyHelen Heslop; Fiscal Year: 2007..Taken together, these program elements especially the mentored laboratory research experience, should provide trainees with a strong foundation for translational research careers in cell and gene therapy. ..
